Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle

Molecular Genetics and Metabolism

Volumn 103, Issue 2, 2011, Pages 107-112

  Koeberl, Dwight D ^a   Luo, Xiaoyan ^a   Sun, Baodong ^a   Mcvie Wylie, Alison ^a,c   Dai, Jian ^a   Li, Songtao ^a   Banugaria, Suhrad G ^a   Chen, Y T ^a,b   Bali, Deeksha S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c GENZYME CORPORATION   (United States)

Author keywords

Acid alpha glucosidase; Acid maltase; Enzyme replacement therapy; Glycogen storage disease type II; Mannose 6 phosphate receptor; Pompe disease

Indexed keywords

ALPHA GLUCOSIDASE; CLENBUTEROL; GLYCOGEN; SOMATOMEDIN B RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENZYME REPLACEMENT; GLYCOGEN STORAGE DISEASE TYPE 2; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SKELETAL MUSCLE; TREATMENT OUTCOME;

ADRENERGIC BETA-AGONISTS; ALPHA-GLUCOSIDASES; ANIMALS; CLENBUTEROL; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; MALE; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; MUSCLE, SKELETAL; RECEPTOR, IGF TYPE 2;

MUS;

EID: 79956275812     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.02.006     Document Type: Article

References (34)

1. Hirschhorn R., Reuser A.J.J. Glycogen storage disease type II: acid α-glucosidase (acid maltase) deficiency. The Metabolic and Molecular Basis for Inherited Disease McGraw-Hill, New York 2001, C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
2. Kishnani P.S., Corzo D., Nicolino M., Byrne B., Mandel H., Hwu W.L., Leslie N., Levine J., Spencer C., Mcdonald M., Li J., Dumontier J., Halberthal M., Chien Y.H., Hopkin R., Vijayaraghavan S., Gruskin D., Bartholomew D., Van Der P.A., Clancy J.P., Parini R., Morin G., Beck M., De La Gastine G.S., Jokic M., Thurberg B., Richards S., Bali D., Davison M., Worden M.A., Chen Y.T., Wraith J.E. Recombinant human acid {alpha}-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
3. Kishnani P.S., Goldenberg P.C., Dearmey S.L., Heller J., Benjamin D., Young S., Bali D., Smith S.A., Li J.S., Mandel H., Koeberl D., Rosenberg A., Chen Y.T. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol. Genet. Metab. 2010, 99:26-33.
4. Ponce E., Witte D.P., Hirschhorn R., Huie M.L., Grabowski G.A. Murine acid α-glucosidase: cell-specific mRNA differential expression during development and maturation. Am. J. Pathol. 1999, 154:1089-1096.
5. Strothotte S., Strigl-Pill N., Grunert B., Kornblum C., Eger K., Wessig C., Deschauer M., Breunig F., Glocker F.X., Vielhaber S., Brejova A., Hilz M., Reiners K., Muller-Felber W., Mengel E., Spranger M., Schoser B. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J. Neurol. 2010, 257:91-97.
6. Van Capelle C.I., Van Der Beek N.A., Hagemans M.L., Arts W.F., Hop W.C., Lee P., Jaeken J., Frohn-Mulder I.M., Merkus P.J., Corzo D., Puga A.C., Reuser A.J., Van Der Ploeg A.T. Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul. Disord. 2010, 20:775-782.
7. Ravaglia S., Danesino C., Moglia A., Costa A., Cena H., Maccarini L., Carlucci A., Pichiecchio A., Bini P., De Filippi P., Rossi M. Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. Eur. J. Neurol. 2010, 17:957-962.
8. Amalfitano A., Bengur A.R., Morse R.P., Majure J.M., Case L.E., Veerling D.L., Mackey J., Kishnani P., Smith W., Mcvie-Wylie A., Sullivan J.A., Hoganson G.E., Phillips Iii J.A., Schaefer G.B., Charrow J., Ware R.E., Bossen E.H., Chen Y.T. Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet. Med. 2001, 3:132-138.
9. Desnick R.J. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inher Metab Dis 2004, 27:385-410.
10. Raben N., Danon M., Gilbert A.L., Dwivedi S., Collins B., Thurberg B.L., Mattaliano R.J., Nagaraju K., Plotz P.H. Enzyme replacement therapy in the mouse model of Pompe disease. Molecr Genet Metab 2003, 80:159-169.
11. Raben N., Fukuda T., Gilbert A.L., De Jong D., Thurberg B.L., Mattaliano R.J., Meikle P., Hopwood J.J., Nagashima K., Nagaraju K., Plotz P.H. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol. Ther. 2005, 11:48-56.
12. Zhu Y., Li X., Mcvie-Wylie A., Jiang C., Thurberg B.L., Raben N., Mattaliano R.J., Cheng S.H. Carbohydrate-remodeled acid alpha-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Neuromuscr Dis 2005, 15:712-713.
13. Mcvie-Wylie A.J., Lee K.L., Qiu H., Jin X., Do H., Gotschall R., Thurberg B.L., Rogers C., Raben N., O'callaghan M., Canfield W., Andrews L., Mcpherson J.M., Mattaliano R.J. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. Mol. Genet. Metab. 2008, 94:448-455.
14. Zhu Y., Jiang J.L., Gumlaw N.K., Zhang J., Bercury S.D., Ziegler R.J., Lee K., Kudo M., Canfield W.M., Edmunds T., Jiang C., Mattaliano R.J., Cheng S.H. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol. Ther. 2009, 17:954-963.
15. Cardone M., Porto C., Tarallo A., Vicinanza M., Rossi B., Polishchuk E., Donaudy F., Andria G., De Matteis M.A., Parenti G. Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 2008, 1:6.
16. Matsumoto T., Akutsu S., Wakana N., Morito M., Shimada A., Yamane A. The expressions of insulin-like growth factors, their receptors, and binding proteins are related to the mechanism regulating masseter muscle mass in the rat. Arch. Oral Biol. 2006, 51:603-611.
17. Raben N., Kanneboyina N., Lee E., Kessler P., Byrne B., Lee L., Lamarca M., King C., Ward J., Sauer B., Plotz P. Targeted disruption of the acid α-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J. Biol. Chem. 1998, 273:19086-19092.
18. Bruning J.C., Michael M.D., Winnay J.N., Hayashi T., Horsch D., Accili D., Goodyear L.J., Kahn C.R. A muscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 1998, 2:559-569.
19. Lynch G.S., Ryall J.G. Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol. Rev. 2008, 88:729-767.
20. Sandri M. Signaling in muscle atrophy and hypertrophy. Physiol. Bethesda 2008, 23:160-170.
21. Mounier R., Cavalie H., Lac G., Clottes E. Molecular impact of clenbuterol and isometric strength training on rat EDL muscles. Pflugers Arch 2007, 453:497-507.
22. Maclennan P.A., Edwards R.H. Effects of clenbuterol and propranolol on muscle mass, evidence that clenbuterol stimulates muscle beta-adrenoceptors to induce hypertrophy. Biochem. J. 1989, 264:573-579.
23. Awede B.L., Thissen J.P., Lebacq J. Role of IGF-1 and IGFBPs in the changes of mass and phenotype induced in rat soleus muscle by clenbuterol. Am. J. Physiol. Endocrinol. Metab. 2002, 282:E31-E37.
24. Shi H., Zeng C., Ricome A., Hannon K.M., Grant A.L., Gerrard D.E. Extracellular signal-regulated kinase pathway is differentially involved in beta-agonist-induced hypertrophy in slow and fast muscles. Am. J. Physiol. Cell Physiol. 2007, 292:C1681-C1689.
25. Burniston J.G., Mclean L., Beynon R.J., Goldspink D.F. Anabolic effects of a non-myotoxic dose of the beta2-adrenergic receptor agonist clenbuterol on rat plantaris muscle. Muscle Nerve 2007, 35:217-223.
26. Plant D.R., Kearns C.F., Mckeever K.H., Lynch G.S. Therapeutic clenbuterol treatment does not alter Ca2+ sensitivity of permeabilized fast muscle fibres from exercise trained or untrained horses. J. Muscle Res. Cell Motil. 2003, 24:471-476.
27. Oya Y., Morita H., Ogawa M., Nonaka I., Tsujino S., Kawai M. Adult form of acid maltase deficiency presenting with pattern of muscle weakness resembling facioscapulohumeral dystrophy. Rinsho Shinkeigaku 2001, 41:390-396.
28. Ryall J.G., Sillence M.N., Lynch G.S. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br. J. Pharmacol. 2006, 147:587-595.
29. Ryall J.G., Plant D.R., Gregorevic P., Sillence M.N., Lynch G.S. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats. J. Physiol. 2004, 555:175-188.
30. Angelini C., Menegazzo E., Marcon M., Marsala S.Z., Roni V. An open trial of albuterol and branched chain aminoacids in adult acid maltase deficiency. Neurology 1998, 50:A369.
31. [31], Angelini E.P.C., Marsala S.Z., Vergani L., Nascimbeni A.C., Fulizio L., Fanin M. Adult acid maltase deficiency: an open trial with albuterol and branched-chain aminoacids. Basic Appl. Myol. 2004, 14:71/78.
32. Wylie A.A., Pulford D.J., Mcvie-Wylie A.J., Waterland R.A., Evans H.K., Chen Y.T., Nolan C.M., Orton T.C., Jirtle R.L. Tissue-specific inactivation of murine M6P/IGF2R. Am. J. Pathol. 2003, 162:321-328.
33. Sun B.D., Zhang H.Y., Franco L.M., Young S.P., Schneider A., Bird A., Amalfitano A., Chen Y.T., Koeberl D.D. Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol. Ther. 2005, 11:57-65.
34. Amalfitano A., Mcvie-Wylie A.J., Hu H., Dawson T.L., Raben N., Plotz P., Chen Y.T. Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-alpha-glucosidase. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:8861-8866.